Go Pro
NYSEAMERICAN:AZTR

Azitra Q3 2025 Earnings Report

Azitra logo
$0.17 0.00 (-2.25%)
Closing price 09/18/2026 04:10 PM Eastern
Extended Trading
$0.18 +0.00 (+2.30%)
As of 09/18/2026 07:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Azitra EPS Results

Actual EPS
-$0.67
Consensus EPS
-$0.79
Beat/Miss
Beat by +$0.12
One Year Ago EPS
N/A

Azitra Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Azitra Announcement Details

Quarter
Q3 2025
Time
Before Market Opens
Conference Call Date
Wednesday, November 12, 2025
Conference Call Time
7:00AM ET

Upcoming Earnings

Azitra's Q3 2026 earnings is estimated for Wednesday, November 11, 2026, based on past reporting schedules, with a conference call scheduled on Thursday, November 12, 2026 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Azitra Earnings Headlines

The end may be near for these iconic stocks
Marc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are triggering a historic wealth transfer already underway in 2026. Household names like Intuit (-57%), Boston Scientific (-49%), and Tractor Supply (-40%) are cratering, while lesser-known companies like Sandisk (+573%) and Rackspace (+444%) surge. Chaikin has identified specific stocks he believes investors should sell before they fall further - and the names may surprise you. He's also pinpointing a company tapped as Nvidia's self-driving partner and a potential AI megadeal that could split into three high-growth stocks. Stream his free presentation to get every buy and sell recommendation with no membership or credit card required.tc pixel
See More Azitra Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Azitra? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Azitra and other key companies, straight to your email.

About Azitra

Azitra (NYSEAMERICAN:AZTR) is a clinical-stage biotechnology company focused on developing precision dermatology treatments for inflammatory and other skin conditions. The company uses engineered microbes and its proprietary platform to discover and develop live biotherapeutic products intended to address disease-related changes in the skin microbiome and deliver therapeutic proteins locally.

Azitra’s product pipeline has included ATR-12, an engineered strain of Staphylococcus epidermidis designed to produce filaggrin-1 for the potential treatment of Netherton syndrome, a rare genetic skin disorder. The company has also developed ATR-04, a topical live biotherapeutic candidate intended to help treat acneiform rash and other skin complications associated with epidermal growth factor receptor inhibitor therapies.

Founded in 2014, Azitra is based in Branford, Connecticut, and conducts its research and development activities in the United States. Its programs are aimed at addressing both rare dermatologic diseases and more common treatment-related skin conditions.

View Azitra Profile